Cefoxitin

證據等級: L5

預測適應症: 10 個

Cefoxitin: From Broad-Spectrum Bacterial Infections to Infectious Otitis Media

One-Sentence Summary

Cefoxitin is a second-generation cephalosporin antibiotic of the cephamycin subclass, traditionally used for intra-abdominal infections, pelvic inflammatory disease (PID), and surgical prophylaxis due to its broad-spectrum and β-lactamase-stable activity. The TxGNN model predicts it may be effective for Infectious Otitis Media, with 0 clinical trials and 2 publications currently supporting this specific direction.

Quick Overview

Item	Content
Original Indication	Broad-spectrum bacterial infections (intra-abdominal infections, PID, surgical prophylaxis)
Predicted New Indication	Infectious Otitis Media
TxGNN Prediction Score	99.30%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Cefoxitin belongs to the cephamycin subclass of β-lactam antibiotics. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking and triggering bacterial lysis. Its hallmark feature — a 7α-methoxy group on the cephalosporin nucleus — confers intrinsic resistance to many β-lactamases, including AmpC-type enzymes, giving it activity against strains that would otherwise resist standard cephalosporins. Detailed mechanism of action data from DrugBank was not available in this evidence pack; the above is based on published pharmacological class knowledge.

Infectious otitis media is predominantly caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis — all organisms covered by cefoxitin’s antibacterial spectrum. The prediction gains additional mechanistic support from cefoxitin’s documented activity against rapidly growing nontuberculous mycobacteria (NTM), particularly Mycobacterium fortuitum, a rare but documented cause of refractory otitis media and mastoiditis where standard antibiotic regimens may fail.

That said, the clinical application of a parenteral antibiotic for infectious otitis media — a condition typically managed with oral agents — would be narrow and reserved for complicated, treatment-resistant, or NTM-attributed cases. The TxGNN model captures the biological plausibility, but clinical feasibility requires further evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered for Cefoxitin in infectious otitis media.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8783722	1996	Case Report + Case Series Review	Clinical Infectious Diseases	Reports Mycobacterium fortuitum as a rare cause of otitis media and mastoiditis across 5 total reviewed cases; highlights amikacin resistance in some isolates, suggesting a need for alternative agents — cefoxitin’s NTM activity is directly relevant to this treatment gap
33061472	2020	Narrative Review	Infection and Drug Resistance	MRSA One Health review noting MRSA as a cause of otitis media among other invasive infections; contextualizes the need for β-lactamase-stable antibiotics, though MRSA (mecA-mediated) is intrinsically resistant to all β-lactams including cefoxitin

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN prediction score is high (99.30%) and the mechanistic basis — particularly cefoxitin’s coverage of NTM pathogens and β-lactamase-producing organisms associated with otitis media — is scientifically plausible, the current evidence consists of only 2 indirect literature references with no registered clinical trials. Furthermore, cefoxitin is not marketed in the Philippines, making immediate clinical application impractical without regulatory groundwork.

To proceed, the following is needed:

Prospective observational or pilot clinical studies directly evaluating cefoxitin for infectious otitis media, particularly in NTM-related or complicated refractory cases
DrugBank MOA data to formally document the mechanistic link between cefoxitin and otitis media pathogens
A clearly defined patient population where parenteral cefoxitin offers a clinical advantage over standard oral first-line therapies (e.g., amoxicillin-clavulanate)
Philippines regulatory registration or compassionate use pathway assessment, as cefoxitin currently has no active licenses in the Philippines
Philippines drug safety information (package insert warnings, contraindications) to complete the S1 safety screening gate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.